COVID-19 pandemic impact on severe asthma patients care in Europe

No registrations found.

Ethical review	Not applicable
Status	Pending
Health condition type	-
Study type	Observational non invasive

Summary

ID

NL-OMON24123

Source

Brief title SHARP-COVID

Health condition

Severe asthma

Sponsors and support

Primary sponsor: SHARP

Source(s) of monetary or material Support: The project is organised by SHARP (Severe Heterogenous Asthma Research collaboration, Patient-centred). SHARP is funded by different stakeholders, including the ERS (Europen Respiratory Society) and industry.

Intervention

Outcome measures

Primary outcome

Description of changes in severe asthma care.

Secondary outcome

1 - COVID-19 pandemic impact on severe asthma patients care in Europe 5-05-2025

Description of changes in asthma control of severe asthma patients as a consequence of changes in severe asthma care.

Study description

Background summary

The SHARP-COVID project is investigating whether the COVID-19 pandemic has impacted the care of patients with severe asthma, and whether changes in severe asthma care have affected asthma control in these patients. For this purpose, questionnaires will be sent to patients with severe asthma and severe asthma specialists from 18 countries across Europe.

Study objective

The COVID-19 pandemic has caused substantial changes in severe asthma care, which may have negatively impacted on patient's asthma control.

Study design

In this cross-sectional study patients will be asked once to fill in an online or paper survey. Also asthma experts will be asked once to complete an online survey including questions on reorganisation of severe asthma care in their center.

The survey system will be closed depending on the progress of the project (we aim for 50 completed patient surveys per country).

Intervention

Online or paper version survey

Contacts

Public Amsterdam University Medical Center Katrien Eger

0205667924 **Scientific** Amsterdam University Medical Center Katrien Eger

0205667924

2 - COVID-19 pandemic impact on severe asthma patients care in Europe 5-05-2025

Eligibility criteria

Inclusion criteria

patients with physician diagnosed severe asthma who are followed up in an asthma clinic for at least 6 months at the beginning of the COVID-19 pandemic

Exclusion criteria

none

Study design

Design

Study type:	Observational non invasive
Intervention model:	Other
Allocation:	Non controlled trial
Masking:	Open (masking not used)
Control:	N/A , unknown

Recruitment

. . .

NL	
Recruitment status:	Pending
Start date (anticipated):	22-11-2020
Enrollment:	900
Туре:	Anticipated

IPD sharing statement

Plan to share IPD: Undecided

Ethics review

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL9063
Other	METC AMC : W20_463 # 20.512

Study results